Editas Medicine, Inc. filings document regulatory disclosures for a clinical-stage genome editing company developing CRISPR-based in vivo medicines. Recent 8-K filings report operating results and financial condition, business highlights, EDIT-401 development disclosures, scientific data furnished under Regulation FD, and other events tied to CRISPR intellectual property matters.
The filing record also includes proxy materials covering board governance, executive compensation and equity awards, along with material-event reporting on a change in independent registered public accounting firm. These disclosures frame the company’s pipeline, capital resources, governance practices, risk areas and public-company reporting obligations.
Editas Medicine, Inc. ownership disclosure: TCG Crossover III entities and Chen Yu report shared beneficial ownership of 15,798,999 shares of Common Stock, representing 9.9% of the class. The total counts include 11,111,111 issued shares plus 4,687,888 shares issuable upon warrants exercisable within 60 days. The filing cites 153,461,838 shares outstanding as of May 27, 2026 following an underwritten offering, and a combined basis of 158,149,726 shares when the exercisable warrants are included.
The reporting persons note a Beneficial Ownership Limitation that prevents exercise of certain warrants to the extent doing so would push ownership above 9.99%. The filing is a joint Schedule 13G by TCG Crossover Fund III, L.P., TCG Crossover GP III, LLC and Chen Yu and includes a joint filing agreement.
Editas Medicine reports a joint Schedule 13G showing Commodore Capital entities and two managing partners may be deemed to beneficially own 16,045,802 shares of common stock, comprising 8,889,000 shares plus rights to 7,156,802 shares underlying common warrants. The filing states ownership percentages are based on 153,461,838 shares outstanding as of May 21, 2026 and that a Beneficial Ownership Limitation of 9.99% applies. The report names Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz as filers and notes shared voting and dispositive power over the disclosed securities.
EDIT notice of proposed resale of Common Stock by an insider. The filing lists 15,000 shares and an associated $46,200 figure, with an exchange noted as NASDAQ and an effective date of 06/03/2026. The filing also records Restricted Stock Unit Vesting of 32,957 shares on 06/02/2026 and a prior sale of 5,394 shares on 03/03/2026 for $10,894.26.
Editas Medicine is offering 55,555,556 shares of common stock and accompanying warrants at a combined public offering price of $2.25 per share-plus-warrant. The offering includes detachable common stock warrants exercisable at $3.50 (or pre-funded alternatives) and is expected to raise approximately $117.0 million in net proceeds to fund development of EDIT-401, clinical and manufacturing costs, and general corporate purposes. The offering assumes 153,461,838 shares outstanding after the offering (assuming no exercise of the new warrants).
Editas Medicine entered into an underwriting agreement for an underwritten public offering of 55,555,556 shares of common stock and accompanying warrants, with each share-plus-warrant unit priced at $2.25. All securities are being sold by the company under an effective shelf registration.
The company expects net proceeds of about $117.0 million after underwriting discounts and expenses, excluding any warrant exercise proceeds. Management estimates that, combined with cash and cash equivalents as of March 31, 2026, this funding will support operations into the second half of 2028, though this outlook depends on assumptions that may change.
Editas Medicine, Inc. filed a current report describing a change to its equity distribution plans with TD Securities (USA) LLC, doing business as TD Cowen. The company has suspended and terminated the existing prospectus supplement for its “at-the-market” stock offering program under the Sales Agreement.
Editas states it will not sell additional common stock through this program unless and until a new prospectus or prospectus supplement is filed and, if needed, a new registration is declared effective by the SEC. The underlying Sales Agreement with TD Cowen remains in effect.
As of May 26, 2026, Editas had issued and sold 14,327,365 shares of common stock under this at-the-market program, generating aggregate gross sale proceeds of $43.9 million before sales commissions and offering expenses.
Editas Medicine is offering shares of common stock, pre-funded warrants and accompanying common stock warrants. The prospectus supplement describes the securities' structure, including combined purchase units (each unit pairs a share or pre-funded warrant with a warrant), exercise prices, ownership limitation mechanics (4.99% or 9.99% initially, increaseable to 19.99% after notice), and the limited exercisability windows for the common stock warrants tied to Phase 1 EDIT-401 clinical data or three years from issuance. The filing discloses 97,906,282 shares outstanding as of April 30, 2026, cash and cash equivalents of $123.6 million as of March 31, 2026, Nasdaq listing under the symbol EDIT, and that net tangible book value was $4.4 million ( $0.05 per share) as of March 31, 2026. Use of proceeds is stated as funding EDIT-401 clinical development and manufacturing, plus working capital and general corporate purposes.
Editas Medicine reported new preclinical results and development plans for EDIT-401, its lead in vivo gene‑editing candidate for hyperlipidemia. In non-human primates, a single dose produced about 90% or greater average reductions in LDL-cholesterol, lipoprotein(a), and apolipoprotein B, key drivers of cardiovascular risk.
At a therapeutically relevant dose of 1.5 mg/kg, EDIT-401 was described as well-tolerated, with no adverse clinical observations, no notable treatment-related liver enzyme elevations, no liver histopathology findings, and a mean functional liver editing rate of 12.4%. Higher doses of 3 mg/kg and 6 mg/kg led to liver enzyme increases and adverse observations at the top dose.
The company plans to submit a Clinical Trial Notification in Australia by mid-2026, aiming to start a first-in-human trial in Heterozygous Familial Hypercholesterolemia later in 2026 and obtain early in vivo human proof-of-concept data by year-end 2026. The proposed Phase 1/2 design includes a Part 1 single ascending dose study in about 18 patients and a Part 2 randomized, placebo-controlled expansion in about 28 patients, with Part 1 topline results expected in 2027. Editas also received FDA pre-IND feedback it believes supports a future U.S. IND for EDIT-401.
Editas Medicine used this 8-K to share new preclinical results for its in vivo CRISPR candidate EDIT-401, being developed as a potential one-time treatment for hyperlipidemia. In non-human primates, a single dose across 1.5–3.0 mg/kg produced ≥90% mean LDL cholesterol reduction that appeared rapidly and remained durable for about six months.
The company reports this effect was achieved with only 10–40% functional editing of LDLR alleles and at least a six-fold mean increase in hepatic LDLR protein, with no adverse clinical observations at the therapeutically relevant 1.5 mg/kg dose. Mouse pharmacokinetic and pharmacodynamic data suggest dose adjustments may not be needed to achieve LDL-C lowering in heterozygous familial hypercholesterolemia patients, supporting continued advancement toward first-in-human studies.
Editas Medicine reported a Q1 2026 net loss of $25.0 million, sharply improved from $76.1 million a year earlier as prior restructuring and impairment charges rolled off and operating costs declined.
Collaboration and other R&D revenue fell to $2.8 million from $4.7 million. Research and development expense dropped to $17.6 million and general and administrative expense to $10.2 million, reflecting the discontinuation of the reni‑cel program and a large workforce reduction completed in 2025.
The company ended March 31, 2026 with $123.6 million in cash and cash equivalents and an accumulated deficit of about $1.7 billion. Management states this cash should fund operations into the third quarter of 2027 while Editas advances lead in vivo gene‑editing candidate EDIT‑401 toward first‑in‑human studies and early proof‑of‑concept data.